Value through Innovation05 August 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

21.05.2015

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

20.05.2015

Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.

20.05.2015

New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy1,2,3

-  
18.05.2015

New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups

18.05.2015

Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes

18.05.2015

Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate

14.05.2015

Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung

13.05.2015

First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation

22.04.2015

2014: Boehringer Ingelheim positioned for future growth with product launches

17.04.2015

New international survey of lung cancer oncologists highlights underutilization of personalized treatments

- For media outside the US, the UK and Canada only
13.04.2015

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders

30.03.2015

Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union

- For media outside the US, the UK and Canada only
20.03.2015

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

 

- For Non-UK / Non-Canadian Media only
16.03.2015

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

- For Non-US/Non-UK/Non-Canadian Media
12.03.2015

EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe

03.03.2015

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

- For Non-US/Non-UK Media
02.03.2015

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe

24.02.2015

Boehringer Ingelheim Animal Health continues support of independent PCV2 research